Pateclizumab Biosimilar - Research Grade

Human

LTA

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P01374

4049

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of pateclizumab, a monoclonal antibody directed against human lymphotoxin-alpha (LT-alpha / TNF-beta), supplied strictly for research use only. It is not the clinical drug and is not intended for human or veterinary use. Built around the LT-alpha target, it is offered as a human IgG1/kappa format suitable for in-vitro and preclinical work where a well-characterised anti-LT-alpha binder is needed. Typical research applications include use as a positive binding control, a neutralisation reagent for probing LT-alpha-driven signalling, a benchmark antibody in comparability or assay-development studies, and a tool for ADCC/effector-function or antibody-engineering workflows. The material is manufactured at research grade with low endotoxin (<1 EU/mg standard; ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities to support screening campaigns, in-vitro assays, and preclinical model systems. Because the target is human LT-alpha, cross-reactivity should be confirmed empirically for the researcher's specific system before use. Lymphotoxin-alpha (LTA), also called TNF-beta or TNFSF1, is a member of the TNF superfamily produced mainly by activated lymphocytes. It exists as a secreted homotrimer that engages TNFR1 (TNFRSF1A), TNFR2 (TNFRSF1B) and HVEM (TNFRSF14), and as a membrane heterotrimer with lymphotoxin-beta (LTA1/LTB2) that signals through the LT-beta receptor (LTBR). Through these receptors LT-alpha drives NF-kappaB activation, pro-inflammatory gene expression, and apoptotic signalling, and is cytotoxic to many tumour cell lines. LT-alpha is essential for the development and organisation of secondary lymphoid organs, germinal centre formation, and high endothelial venule maintenance. Dysregulated LT-alpha signalling is implicated in chronic inflammatory and autoimmune disease, making it a target of interest in immunology research.

LT-alpha, TNF-beta, Tumor necrosis factor ligand superfamily member 1, Lymphotoxin-alpha, TNFB, TNFSF1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Pateclizumab (anti-LTA) Biosimilar

Q: Is the Pateclizumab biosimilar available in bulk or gram quantities?

A: Yes — the Pateclizumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Pateclizumab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Pateclizumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Pateclizumab that binds LTA; for research use only (RUO).